Regentis Biomaterials grants director options, warrants

Regentis Biomaterials director Jeff Dykan reported equity compensation consisting of 24,826 employee stock options with a $2.1600 exercise price and 12,500 warrants with a $0.0030 exercise price, each for ordinary shares.

Rhea-AI Filing Summary

Regentis Biomaterials director Jeff Dykan reported equity compensation consisting of 24,826 employee stock options with a $2.1600 exercise price and 12,500 warrants with a $0.0030 exercise price, each for ordinary shares. The options vest quarterly over three years until fully vested on May 28, 2029, while the warrants are currently exercisable for a three-year term through February 23, 2029. Both awards were approved by the board and became effective after shareholder approval on July 9, 2026.

Filing Explained

The filing records director awards—not current share issuance—with one warrant exercisable now and one option beginning vesting August 28, 2026.

The July 13, 2026 Form 4 reports that a Regentis Biomaterials director acquired two derivative securities on July 9, 2026: a warrant tied to 12,500 ordinary shares and an employee stock option tied to 24,826 ordinary shares.

These entries are grants, identified by transaction code A, not exercises or reported issuances, so the filing discloses rights that may lead to future ordinary-share issuance rather than shares issued in this filing.

Form 4 reports an insider transaction, and code A denotes a grant or award; the warrant is currently exercisable and expires on February 23, 2029.

The option first vests on August 28, 2026, then vests in quarterly one-twelfth installments subject to continued employment, and is scheduled to fully vest on May 28, 2029.

Insider Trade Summary

Grant/Award: 37,326 shares

Grant/Award 2 txns

Insider Dykan Jeff

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Warrants to purchase ordinary shares F1, F2	12,500	$0.00	$0.00
Grant/Award	Employee Stock Option (Right to Buy) F3, F4, F5	24,826	$0.00	$0.00

Holdings After Transaction: Warrants to purchase ordinary shares — 12,500 contracts (Direct); Employee Stock Option (Right to Buy) — 24,826 contracts (Direct)

Footnotes (5)

1. F1. This warrant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026.
2. F2. The warrants are currently exercisable and have a three year term.
3. F3. This option grant was approved by the Board of Directors of the Issuer on May 28, 2026, subject to shareholder approval, which was obtained on July 9, 2026.
4. F4. This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on August 28, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or May 28, 2029.
5. F5. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2024 Share Option Plan must be registered in the name of a trustee.

Key Figures

Employee stock options granted: 24,826 options Option exercise price: $2.1600 per share Option expiration date: May 28, 2036 +4 more

7 metrics

Employee stock options granted 24,826 options Derivative grant to director Jeff Dykan on July 9, 2026

Option exercise price $2.1600 per share Exercise price of 24,826 employee stock options over ordinary shares

Option expiration date May 28, 2036 Expiration of employee stock options granted to Jeff Dykan

Warrants granted 12,500 warrants Derivative warrant grant to purchase ordinary shares on July 9, 2026

Warrant exercise price $0.0030 per share Exercise price of 12,500 warrants over ordinary shares

Warrant expiration date February 23, 2029 End of three-year term for 12,500 warrants

Option vesting period 3 years Options vest quarterly until fully vested on May 28, 2029

Key Terms

Employee Stock Option (Right to Buy), Section 102 of the Israeli Tax Ordinance, 2024 Share Option Plan, vest on a quarterly basis

4 terms

Employee Stock Option (Right to Buy) financial

"Security title is listed as Employee Stock Option (Right to Buy) for 24,826 shares"

Section 102 of the Israeli Tax Ordinance regulatory

"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance"

2024 Share Option Plan financial

"securities issued to an employee in connection with the Issuer's 2024 Share Option Plan must be registered"

vest on a quarterly basis financial

"This options grant shall vest on a quarterly basis, with one-twelfth vesting on August 28, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Regentis Biomaterials (RGNT) grant to director Jeff Dykan?

Regentis Biomaterials granted Jeff Dykan 24,826 employee stock options with a $2.1600 exercise price and 12,500 warrants with a $0.0030 exercise price, each over ordinary shares, as part of his reported equity compensation.

What are the vesting terms of Jeff Dykan’s stock options at Regentis Biomaterials (RGNT)?

The options granted to Jeff Dykan vest on a quarterly basis over three years. One-twelfth vests on August 28, 2026, with additional one-twelfth tranches vesting every three months until full vesting on May 28, 2029, subject to continuous service.

When do Jeff Dykan’s warrants and options at Regentis Biomaterials (RGNT) expire?

Jeff Dykan’s warrants expire on February 23, 2029, and his stock options expire on May 28, 2036. The warrants have a three-year term and are currently exercisable, while the options provide a longer-term incentive horizon.

What approvals were required for the RGNT equity awards reported for Jeff Dykan?

Both the warrants and stock options were approved by the board and made effective only after shareholder approval on July 9, 2026. The warrants were originally approved on February 23, 2026, and the options on May 28, 2026.

How does Israeli tax law affect Jeff Dykan’s RGNT equity awards?

To qualify for tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under Regentis Biomaterials’ 2024 Share Option Plan must be registered in the name of a trustee, affecting how the awards are held for tax purposes.

Are Jeff Dykan’s warrants at Regentis Biomaterials (RGNT) currently exercisable?

Yes. The filing states that the warrants are currently exercisable and have a three-year term. They relate to 12,500 ordinary shares at a $0.0030 exercise price and expire on February 23, 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 05:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dykan Jeff

(Last) (First) (Middle)

C/O REGENTIS BIOMATERIALS LTD.

60 MEDINAT HAYHEHUDIM

(Street)

HERZLIYA 4676652

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENTIS BIOMATERIALS LTD. [ RGNT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants to purchase ordinary shares(1)(2)	$0.003	07/09/2026		A		12,500		02/23/2026	02/23/2029	Ordinary Shares	12,500	$0	12,500	D
Employee Stock Option (Right to Buy)(3)(4)(5)	$2.16	07/09/2026		A		24,826		08/28/2026	05/28/2036	Ordinary Shares	24,826	$0	24,826	D

Explanation of Responses:

1. This warrant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026.

2. The warrants are currently exercisable and have a three year term.

3. This option grant was approved by the Board of Directors of the Issuer on May 28, 2026, subject to shareholder approval, which was obtained on July 9, 2026.

4. This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on August 28, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or May 28, 2029.

5. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2024 Share Option Plan must be registered in the name of a trustee.

	/s/ Jeff Dykan	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)